Importantly, allogeneic-HSCT (allo-HSCT) appeared to be more beneficial in patients with persistent MRD than those who were MRD negative, suggesting that allo-HSCT should perhaps be preferentially recommended to patients with standard risk NPM1 wild type AML with positive MRD after induction [9]. Here, NPM1 is linked to acute myeloid leukemia.